| Gefitinib | A tyrosine kinase inhibitor used as first-line therapy to treat non-small cell lung carcinoma (NSCLC) that meets certain genetic mutation criteria. |
| Sorafenib | A kinase inhibitor used in the treatment of unresectable liver carcinoma and advanced renal carcinoma. |
| Erlotinib | An EGFR tyrosine kinase inhibitor used to treat certain small cell lung cancers or advanced metastatic pancreatic cancers. |
| Imatinib | A tyrosine kinase inhibitor used to treat a number of leukemias, myelodysplastic/myeloproliferative disease, systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors. |
| Sirolimus | An immunosuppressant used to prevent organ transplant rejections and to treat lymphangioleiomyomatosis. |
| Dasatinib | A tyrosine kinase inhibitor used for the treatment of lymphoblastic or chronic myeloid leukemia with resistance or intolerance to prior therapy. |
| Lapatinib | An antineoplastic agent and tyrosine kinase inhibitor used for the treatment of advanced or metastatic HER-negative breast cancer in patients who received prior chemotherapeutic treatments. |
| Sunitinib | A receptor tyrosine kinase inhibitor and chemotherapeutic agent used for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). |
| Everolimus | A mammalian target of rapamycin (mTOR) kinase inhibitor used to treat various types of malignancies. |
| Nilotinib | A kinase inhibitor used for the chronic phase treatment of Chronic Myeloid Leukemia (CML) that is Philadelphia chromosome positive and for the treatment of CML that is resistant to therapy containing imatinib. |
| Cobimetinib | An antineoplastic agent and selective inhibitor of the mitogen-activated extracellular kinase (MEK) pathway used to treat unresectable or metastatic melanoma. |
| Vandetanib | An antineoplastic kinase inhibitor used to treat symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. |
| Temsirolimus | A antineoplastic agent used in the treatment of renal cell carcinoma (RCC) that works by inhibiting mTOR. |
| Pazopanib | An antineoplastic agent used in the treatment of advanced renal cell cancer and advanced soft tissue sarcoma in patients with prior chemotherapy. |
| Midostaurin | An antineoplastic agent used to treat high-risk acute myeloid leukemia (AML) with specific mutations, aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell leukemia (MCL). |
| Bosutinib | An antineoplastic agent used for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adults with inadequate clinical response to other treatments. |
| Axitinib | An oral VEGFR and kinase inhibitor used for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. |
| Crizotinib | A receptor tyrosine kinase inhibitor used to treat metastatic non-small cell lung cancer (NSCLC) where the tumors have been confirmed to be anaplastic lymphoma kinase (ALK), or ROS1-positive. |
| Cabozantinib | A tyrosine kinase inhibitor used to treat advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. |
| Ruxolitinib | A kinase inhibitor used to treat various types of myelofibrosis, polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat graft-versus-host disease in cases that are refractory to steroid treatment. |
| Vemurafenib | A kinase inhibitor used to treat patients with Erdheim-Chester Disease who have the BRAF V600 mutation, and melanoma in patients who have the BRAF V600E mutation. |
| Regorafenib | A kinase inhibitor used to treat patients with metastatic colorectal cancer, unresectable, locally advanced, or metastatic gastrointestinal stromal tumors, and hepatocellular carcinoma. |
| Ponatinib | A kinase inhibitor used to treat patients with various types of chronic myeloid leukemia (CML). |
| Trametinib | A kinase inhibitor used to treat patients with specific types of melanoma, non-small cell lung cancer, and thyroid cancer. |
| Dabrafenib | A kinase inhibitor used to treat patients with specific types of melanoma, non-small cell lung cancer, and thyroid cancer. |
| Afatinib | An antineoplastic agent used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with non-resistant EGFR mutations or resistance to platinum-based chemotherapy. |
| Ibrutinib | An antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's Macroglobulinemia. |
| Idelalisib | An antineoplastic kinase inhibitor used to treat chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). |
| Ceritinib | An antineoplastic kinase inhibitor used to treat anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) in patients with inadequate clinical response or intolerance to crizotinib. |
| Palbociclib | An endocrine-based chemotherapeutic agent used in combination with other antineoplastic agents to treat HER2-negative and HR-positive advanced or metastatic breast cancer. |
| Lenvatinib | A receptor tyrosine kinase inhibitor used for the treatment of metastatic thyroid cancer, advanced renal cell carcinoma in combination with everolimus, and unresectable hepatocellular carcinoma. |
| Nintedanib | A triple angiokinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and in combination with docetaxel for non-small cell lung cancer. |
| Osimertinib | A tyrosine kinase inhibitor used in the treatment of certain types of non-small cell lung carcinoma. |
| Alectinib | A kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. |
| Acalabrutinib | A Bruton tyrosine kinase inhibitor used to treat mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. |
| Ribociclib | A kinase inhibitor used to treat HR+, HER2- advanced or metastatic breast cancer. |
| Neratinib | A protein kinase inhibitor used to treat breast cancer that over expresses the HER2 receptor. |
| Abemaciclib | A medication used to treat HR+ HER2- advanced or metastatic breast cancer. |
| Brigatinib | An anaplastic lymphoma kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. |
| Copanlisib | A medication used to treat relapsed follicular lymphoma who have attempted at least two other treatments. |
| Lorlatinib | An anaplastic lymphoma kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. |
| Pemigatinib | A kinase inhibitor used to treat locally advanced or metastatic, unresectable cholangiocarcinoma in previously treated adult patients. |